Search

Your search keyword '"Louise C, Brown"' showing total 2 results
Start Over Author "Louise C, Brown" Topic antineoplastic combined chemotherapy protocols
2 results on '"Louise C, Brown"'

1. Inhibition of WEE1 Is Effective in

Author

Jenny F, Seligmann, David J, Fisher, Louise C, Brown, Richard A, Adams, Janet, Graham, Philip, Quirke, Susan D, Richman, Rachel, Butler, Enric, Domingo, Andrew, Blake, Emma, Yates, Michael, Braun, Fiona, Collinson, Rob, Jones, Ewan, Brown, Emma, de Winton, Timothy C, Humphrey, Mahesh, Parmar, Richard, Kaplan, Richard H, Wilson, Matthew, Seymour, and Timothy S, Maughan

Subjects
Male, Cell Cycle Proteins, Pyrimidinones, Middle Aged, Protein-Tyrosine Kinases, Prognosis, Survival Rate, Antineoplastic Combined Chemotherapy Protocols, Mutation, Quality of Life, ras Proteins, Humans, Pyrazoles, Female, Enzyme Inhibitors, Neoplasm Metastasis, Tumor Suppressor Protein p53, Colorectal Neoplasms, Watchful Waiting, Follow-Up Studies
Abstract

Outcomes inPatients with newly diagnosed mCRC were registered into FOCUS4 and tested forFOCUS4-C was conducted between April 2017 and Mar 2020 during which time 718 patients were registered; 247 (34%) wereIn this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for

Published
2021

2. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Author

Gerhardt Attard, Laura Murphy, Noel W Clarke, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Lisa Capaldi, Norma Sidek, Peter Whelan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Ian Sayers, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, and Donat Durr

Subjects
Male, Prostatectomy, Prednisolone, Abiraterone Acetate, Prostatic Neoplasms, 610 Medicine & health, General Medicine, Disease-Free Survival, Progression-Free Survival, SDG 3 - Good Health and Well-being, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Nitriles, Phenylthiohydantoin, Humans, Multicenter Studies as Topic, Neoplasm Grading, Neoplasm Recurrence, Local, Randomized Controlled Trials as Topic
Abstract

BACKGROUND Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population. METHODS These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA] concentration ���40 ng/mL) or relapsing with high-risk features (���12 months of total ADT with an interval of ���12 months without treatment and PSA concentration ���4 ng/mL with a doubling time of

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results